{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:31:49Z","timestamp":1787700709522,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":254,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.rmcr.2025.102283","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T01:00:25Z","timestamp":1758070825000},"page":"102283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cytokine release syndrome caused by dual immunotherapy with tremelimumab and durvalumab: A case report"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7896-9637","authenticated-orcid":false,"given":"Takanori","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Imakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminobu","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2025.102283_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rmcr.2025.102283_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","article-title":"COVID-19 infection: an overview on cytokine storm and related interventions","volume":"19","author":"Montazersaheb","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.rmcr.2025.102283_bib3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.rmcr.2025.102283_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.rmcr.2025.102283_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmcr.2025.102283_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmcr.2025.102283_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jtho.2023.10.010","article-title":"Five cases of cytokine release syndrome in patients receiving cytotoxic chemotherapy together with nivolumab plus ipilimumab: a case report","volume":"19","author":"Shiraishi","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2025.102283_bib8","article-title":"Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - a case report and review of the literature","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.rmcr.2025.102283_bib9","article-title":"Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: a case report with cytokine and damage-associated molecular pattern analysis","author":"Ozaki","year":"2024","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.rmcr.2025.102283_bib10","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.21037\/tlcr-24-444","article-title":"Esophagomediastinal fistula during durvalumab plus tremelimumab with chemotherapy in angiotensin-converting enzyme 2-positive non-small cell lung cancer: a case report","volume":"13","author":"Sumi","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102283_bib11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.rmcr.2025.102283_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.rmcr.2025.102283_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.rmcr.2025.102283_bib14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102283_bib15","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2025.102283_bib16","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102283_bib17","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.cllc.2021.10.012","volume":"23","author":"Shiraishi","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.rmcr.2025.102283_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.rmcr.2025.102283_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:41:28Z","timestamp":1770972088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007125001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":19,"alternative-id":["S2213007125001194"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102283","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine release syndrome caused by dual immunotherapy with tremelimumab and durvalumab: A case report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102283"}}